Mechanism of action of antidepressants and therapeutic perspectives;Mécanisme d'action des antidépresseurs et perspectives thérapeutiques

Therapie

Volumn 57, Issue 4, 2002, Pages 385-396

  Bourin, M ^a   David, D J P ^b   Jolliet, P ^a   Gardier, A ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Antidepressants; Mood disorders; Serotonin receptors

Indexed keywords

ADOFEN; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BRAIN DERIVED GROWTH FACTOR; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXEREN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; FROSINOR; GUANINE NUCLEOTIDE BINDING PROTEIN; IMIPRAMINE; LUDIOMYL; MAPROTILINE; MIANSERIN; MILNACIPRAN; MIRTAZAPINE; NEUROTROPHIC FACTOR; NORADRENALIN UPTAKE INHIBITOR; NORSET; NORTRIPTYLINE; PAROXETINE; REBOXETINE; RENEURON; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; TOLOXAMINE; TRANSCRIPTION FACTOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE;

ANXIETY NEUROSIS; BRAIN REGION; CONFERENCE PAPER; DEPRESSION; DRUG ACTIVITY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; ELECTROPHYSIOLOGY; HUMAN; MONOAMINERGIC SYSTEM; NEUROTRANSMISSION; OBSESSION; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SIGNAL TRANSDUCTION; SYNAPSE;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER; HUMANS; RECEPTORS, SEROTONIN;

EID: 0036661125     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-608
2. Schildkaut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry 1965; 122: 509-522
3. Coppen A. Biochemistry of affective disorders. Br J Psychiatry 1967; 113: 1237-1264
4. Bunney WE, Davis J. Norepinephrine in depressive reactions: a review. Arch Gen Pyschiatry 1965; 13: 483-494
5. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001; 25: 836-844
6. Frazer A. Serotonergic and noradreneregic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001; 62 (suppl 12): 16-23
7. 1B receptors with antidepressants drugs in the mouse forced swimming test. Eur J Pharmacol 1996; 368: 213-220
8. Blier P, De Montigny C. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J Neurosci 1983; 3: 1270-1278
9. 1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuoropharmacology 2000; 39: 110-122
10. Bel N, Artigas F. Chronic treatment with fluvoxamine increase extracellular serotonin in frontal cortex but not in raphe nuclei. Synapse 1993; 15: 243-245
11. 1A autoreceptors in the mechanism of action of serotoninergic antidepressant drugs: recent finding from in vivo microdialysis studies. Fundam Clin Pharmacol 1996; 10: 16-27
12. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 1994; 51: 248-251
13. 1A antagonists. Trends Neurosci 1996; 19: 378-383
14. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 1995; 15: 217-222
15. Perez V, Gilaberte I, Faries D, et al. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 1997; 349: 1594-1597
16. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Pharmacol 1997; 17: 446-450
17. Berman RM, Darnell AM, Miller HL, et al. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 1997; 154: 37-43
18. Berman RM, Anand A, Cappiello A, et al. The use of pindolol with fluoxetine in the treatment of major depression: final results from a double-blind, placebo-controlled trial. Biol Psychiatry 1999: 45: 1170-1177
19. Tome MB, Isaac MT, Harte R, et al. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int Clin Psychopharmacol 1997; 12: 81-89
20. Bourin M, Colombel MC, Nizard J, et al. Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 343-351
21. 1B receptors in old mice. Psychopharmacology 2001: 152: 443-449
22. Gozlan H, Daval G, Verge D, et al. Aging associated in serotoninergic and dopaminergic pre- and postsynaptic neurochemical markers in the rat brain. Neurobiol Aging 1990: 11: 437-449
23. 1B de la sérotonine et effets antidépresseurs des inhibiteurs de recapture sélectifs de la sérotonine. CR Acad Sci 2001; 324: 433-441
24. Redrobe JP, Bourin M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology 1998; 138: 198-206
25. Gobert A, Rivet JM, Cistarelli L, et al. Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin 1A receptors and blockade of alpha2-adrenergic receptors underlie its actions. Neuroscience 1999; 93: 1251-62
26. 2 receptor by in situ hybridisation histochemistry. Correlation with the distribution of receptor sites. Brain Res 1990; 524, 139-143
27. 2C receptors in the rat choroids plexus. Neuropsychopharmacology 1996; 15: 143-151
28. 2C receptor agonists exhibits antidepressant-like properties in the anhedonia model of depression in rats. Eur Neuropsychopharmacol 1993: 6: 169-175
29. Deakins JFW, Guimaraes FS, Wang M, et al. Experimental tests of the 5-HT receptor imbalance theory of affective disturbance. In: 5-Hydroxytryptamine in Psychiatry-A Spectrum of Ideas. Eds: Sandler M, Coppen A, Hamett S, Oxford University Press, Oxford. 1991
30. Randrup A, Munkvad I, Fog R. Mania, depression, and brain dopamine. In: Essman WB & Valzelli L Eds: Current developments in psychopharmacology. New York: Spectrum Publications, 1975: 207-209
31. Renard CE, Fiocco AJ, Clenet F, et al. Is dopamine implicated in the antidepressant-like effect of selective serotonin reuptake inhibitors in the mouse forced swimming test? Psychopharmacology 2001; 158: 198-204
32. Gobert A, Rivet M, Cistarelli L, et al. alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats. J Neurochem 1997; 69: 2616-2619
33. Murck H, Frieboes RM, Antonijevic IA, et al. Distinct temporal pattern of the effects of the combined serotonin-reuptake inhibitor and 5-HT1A agonist EMD 68843 on the sleep EEG in healthy men. Psychopharmacology 2001; 155: 187-192
34. 1A receptor partial agonist properties. Behav Pharmacol 1999; 19: 119-130
35. Nibuya M, Neslter EJ, Duman RS. Chronic antidepressant administration increases the expression of camp response element binding protein (CREB) in rat hippocampus. J Neurosci 1996; 16: 2635-2372
36. Martin A, Kaufmann J, Chamey D. Pharmacotherapy of early-onset depression. Update and new directions. Child Adolesc Psychiatry Clin 2000: 9: 135-157
37. Vollmayr B, Faust H, Lewicka S, et al. Brain-derivated neurotrophic-factor (BDNF) stress response in rats bred for learned helplessness. Mol Psychiatry 2001; 6: 471-474
38. Smith MA, Makino S, Kvetnanasky R, et al. Stress alters the express of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci 1995; 15: 1768-1777
39. Sklair-Tavron L, Nestler EJ. Opposing effects of morphine and the neurotrophins, NT-3, NT-4, and BDNF, on locus coeruleus neurons in vitro. Brain Res 1995; 702: 117-125
40. Moor M, Honegger UE, Weissman UN. Organospecific qualitative changes in the phospholipid composition of rats after chronic administration of the antidepressant drug, desipramine. Biochem Pharmacol 1987; 37: 2035-2039
41. Sulser F, Vetulani J, Mobley PL. Mode of action of antidepressant drugs. Biochem Pharmacol 1978; 27: 257-261
42. Redrobe JP, Bourin M, Colombel MC, et al. Psychopharmacological profile of the selective serotonin reuptake inhibitor, paroxetine: implication of noradrenergic and serotonergic mechanisms. J Psychopharmacol 1998; 12: 348-355
43. Redrobe JP, Bourin M, Colombel MC, et al. Dose-dependent noradrenergic and serotoninergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 1998; 138: 1-8
44. Sheline YI, Sanghavi M, Mintun MA, et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosc 1999; 19: 5034-5043
45. Sheline YI, Wany P, Gado MH, et al. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci USA 1996; 93: 3908-3913
46. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, Delaney RC, McCarthy G, Charney DS, Inis RB. MRI-based measurement of hippocampal volume in patients with combat-related post-traumatic disorder. Am J Psychiatry 1995; 152: 973-981
47. Bremner JD, Narayan M, Anderson ER, et al. Smaller hippocampal volume in major depression. Am J Psychiatry 2000; 157: 115-117
48. Steffens D, Byrum CE, McQuoid DR, et al. Hippocampal volume in geriatric depression. Biol Psychiatry 2000; 48: 301-309
49. Liebowitz MR. Reversible MAO inhibitors in social phobia, bulimia and other disorders. Clin Neuropharm. 1992; 15 (suppl 1): 434A-435A
50. Klein DF. Anxiety reconceptualized. In: Klein DF, Rabkin J. Eds. Anxiety: New research and changing concepts, New-York, Raven Press, 1981: 235-263
51. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder. A placeo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993; 50: 884-895